Molecular Profiling of Gynaecologic Malignancies: A Review
Department of Biochemistry, Sri Siddhartha Medical College, BH Road, Agalakote, Karnataka, India
- *Corresponding Author:
- Shilpa V
Department of Biochemistry
Sri Siddhartha Medical College
BH Road, Agalakote
Tumkur-572107, Karnataka, India
Tel: +91 9739316271
E-mail: [email protected]
Recieved date: December 30, 2015; Accepted date: February 1, 2016; Published date: February 4, 2016
Citation: Shilpa V (2016) Molecular Profiling of Gynaecologic Malignancies: A Review. Hereditary Genet 5:158. doi:10.4172/2161-1041.1000158
Copyright: © 2015 Shilpa V. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The current pathological methods and existing serum tumor markers for gynaecologic malignancies does not provide efficient information regarding the therapeutic intervention to which a cancer responds. Cancers classified based on the molecular profile determines the abnormalities at the genetic level. This in turn has led to the discovery of cancer-specific biomarkers. The cancer-specific biomarkers are used against target specific gene products or pathways. A molecular profile includes both genetic and epigenetic signatures which are specific to a particular type of cancer. Genetic and epigenetic markers are more sensitive and specific which may be efficient in early diagnosis of cancer and aids in multiple therapeutic alternatives. In future, a combination of various biomarkers from genomics (genes, micro RNA [miRNA], mutations, Single Nucleotide Polymorphisms [SNPs]), proteomics (peptides, proteins, modifications) and metabolomics (small-molecule intermediates, hormones, systemic compounds) will provide a promising assay platform that suits specific treatment options.